To Evaluate the add on effect of Virechana followed by Basti on Mitochondrial Dysfunction assessed through Humanin in Patient of Type 2 Diabetes (Prameha) – An open labelled Randomized Standard Controlled Clinical Trial.
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Increase Sr. Humanin (HN) level
研究概览
简要总结
this research explores whether an ayurvedic treatment like virechana and basti can help to improve the health in diabetes patients. in type two diabetes the tiny power plants in our cells called mitochondria don’t work properly. this can lower energy levels make the body less responsive to insulin and allow harmful waste to build up inside and around cells. ayurvedic treatment like virechana might belp by flushing out these wastes improving how these cell power plants work. another treatment basti improves gut health which can boost mitochondrias function by producing helpful enzymes and hormones. the study will test panchakarma procedure like virechana and busti which can enhance the activity of mitochondria in diabetic patient. 100 patients aged between 30 to 60 years with fbs 126mg/dl or ppbs 200mg/dlpatient having symptoms of type 2 diabetes will participate they will be divided into two groups in group A 50 patients will receive virechana and basti and in group B 50 patient will receive metformin. study period is four weeks symptoms of diabetes biomarkers and who DQOL will be assessed before and after treatment if any positive findings are obtained in mitochondrial dysfunction then it will be great boost to explore this part of the treatment in future and treatment plan for many diseases can be made by considering this abnormality of the cell
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 30.00 Year(s) 至 65.00 Year(s)(—)
- 性别
- All
入选标准
- •Patient having three or more signs and symptoms of the disease. Freshly diagnosed patients and patient with ongoing medication (metformin/combination of metformin) of Type 2 Diabetes with blood sugar level- FBS.
- •126 to 220 mg/dl or PPBS.
- •200 to 300 mg/dl or Age group of 30-65 years. Patient fit for Virechana and Basti Karma.
排除标准
- 未提供
结局指标
主要结局
Increase Sr. Humanin (HN) level
时间窗: 4th week of treatment
次要结局
- Reduction the levels FBS & PPBS(Improvement in the quality of Life in Diabetic Patients.)
